In Vivo CAR-T: The Race to Turn Cell Therapy into an Injectable Drug

https://gunjanohri.github.io/In-vivo-CAR-T-report/

For years, CAR-T therapy has represented one of the most powerful breakthroughs in cancer treatment. Patients with otherwise untreatable blood cancers have achieved durable remissions after receiving genetically engineered T cells designed to hunt tumors with precision.

But there has always been a catch: manufacturing CAR-T cells is painfully complex.

Today’s approved CAR-T therapies require extracting a patient’s T cells, shipping them to specialized facilities, genetically engineering them outside the body, expanding them under GMP conditions, and then reinfusing them weeks later. The process is expensive, labor-intensive, and often too slow for critically ill patients.

A new generation of researchers and biotech companies is now trying to eliminate that bottleneck entirely.

Instead of engineering immune cells in a factory, they want to engineer them directly inside the patient.

The field is called in vivo CAR-T therapy, and it may redefine how cellular immunotherapy is delivered over the next decade.

The Core Idea: Reprogram T Cells Inside the Body

Traditional CAR-T therapy works like custom manufacturing.

In vivo CAR-T aims to work more like software delivery.

Instead of removing T cells and modifying them externally, researchers deliver genetic instructions directly into circulating immune cells using viral vectors or lipid nanoparticles (LNPs). Once inside the body, endogenous T cells begin expressing chimeric antigen receptors (CARs) capable of recognizing and destroying cancer cells.

The conceptual shift is enormous.

If successful, in vivo CAR-T could:

• eliminate leukapheresis
• reduce manufacturing timelines from weeks to days
• lower costs dramatically
• simplify logistics
• make CAR-T accessible to far more patients worldwide

Researchers increasingly describe the vision as transforming CAR-T from a bespoke medical procedure into an “off-the-shelf” programmable medicine.

Why Current CAR-T Manufacturing Doesn’t Scale

Approved CAR-T therapies have demonstrated extraordinary efficacy in hematologic malignancies, especially CD19-positive leukemias and lymphomas. But scaling the model globally remains difficult.

The current workflow includes:

1. collecting patient T cells
2. genetic modification in specialized facilities
3. cell expansion
4. extensive quality control
5. cryopreservation and shipping
6. reinfusion after lymphodepletion

Each batch is individualized for a single patient. Manufacturing can take weeks and cost hundreds of thousands of dollars.

For aggressive cancers, delays can be clinically devastating.

In vivo engineering attempts to remove most of these operational constraints.

The Technologies Powering In Vivo CAR-T

Several delivery strategies are competing to become the dominant platform.

1. Viral Vectors

Lentiviral and adeno-associated viral (AAV) systems remain attractive because they can efficiently insert CAR genes into T cells and sustain long-term expression.

Advantages include:

• high transduction efficiency
• durable CAR expression
• extensive prior gene therapy experience

But the risks are substantial:

• insertional mutagenesis
• off-target transduction
• immune reactions against viral capsids
• difficulty with repeat dosing

These concerns become even more important when gene delivery occurs systemically inside the body rather than in controlled ex vivo settings.

2. Lipid Nanoparticles (LNPs)

LNPs emerged as a transformative delivery platform during the mRNA vaccine era, and they are now being adapted for immunotherapy.

Instead of integrating DNA permanently, LNPs often deliver mRNA transiently, enabling temporary CAR expression.

This creates several advantages:

• reduced genomic risk
• easier repeat dosing
• simpler manufacturing
• programmable delivery payloads

A landmark 2020 study demonstrated that mRNA nanocarriers could transiently engineer circulating T cells in vivo, providing early proof that systemic CAR programming was feasible.

Today, many researchers see targeted LNPs as one of the most promising routes for scalable in vivo immune engineering.

The Biggest Challenge: Hitting the Right Cells

Delivering genetic cargo into the body sounds elegant in theory.

In practice, it introduces a targeting nightmare.

The human body is extraordinarily efficient at clearing foreign particles. Many delivery vehicles naturally accumulate in the liver, spleen, or other unintended tissues. Achieving selective delivery to circulating T cells remains one of the field’s hardest problems.

Off-target transduction could create serious safety risks.

Researchers are now developing:

• antibody-targeted nanoparticles
• cell-specific ligands
• logic-gated CAR systems
• tunable expression controls
• transient RNA delivery approaches

The goal is precise immune programming without uncontrolled systemic effects.

Safety Still Looms Large

Even conventional CAR-T therapies can trigger dangerous toxicities such as:

• cytokine release syndrome (CRS)
• immune effector cell-associated neurotoxicity syndrome (ICANS)

In vivo approaches inherit these risks while adding entirely new ones:

• vector immunogenicity
• biodistribution unpredictability
• uncontrolled CAR expression
• innate immune activation
• long-term genomic safety concerns

Because engineering occurs directly inside patients, regulators may require even stricter monitoring frameworks than current ex vivo CAR-T therapies.

This regulatory uncertainty remains one of the field’s largest translational bottlenecks.

Beyond Cancer: Programmable Immunity

One of the most exciting aspects of in vivo CAR-T may be its expansion beyond oncology.

Researchers are already exploring applications in:

• autoimmune disease
• inflammatory disorders
• transplantation
• infectious disease

Recent studies have shown remarkable responses using CD19-directed CAR-T approaches in refractory autoimmune diseases such as systemic lupus erythematosus.

If immune cells can be programmed safely inside the body, entirely new therapeutic categories may emerge.

Some scientists now describe this future as programmable immunity — using genetic delivery systems to dynamically rewire immune behavior in real time.

Solid Tumors: The Ultimate Test

Blood cancers have been the early success story for CAR-T.

Solid tumors remain far more difficult.

Challenges include:

• immunosuppressive tumor microenvironments
• antigen heterogeneity
• poor T-cell infiltration
• T-cell exhaustion

These limitations affect both ex vivo and in vivo CAR-T approaches.

Still, researchers are developing:

• multi-antigen CAR systems
• spatially optimized CAR designs
• myeloid-cell engineering approaches
• programmable cytokine payloads

New in vivo screening methods are helping identify CAR architectures better suited for hostile tumor environments such as pancreatic cancer.

The Industry Is Moving Fast

The pace of innovation is accelerating rapidly.

Academic labs, startups, and major biotech companies are now competing across:

• targeted nanoparticles
• viral delivery systems
• transient mRNA programming
• immune cell reprogramming platforms

Some early clinical studies have already demonstrated proof-of-concept responses in patients with relapsed or refractory malignancies.

The field is still early.

But the direction is becoming clearer: the future of cell therapy may involve fewer factories and more programmable biology.

The Bigger Picture

In vivo CAR-T is not simply an incremental improvement to existing immunotherapy.

It represents a broader shift in medicine.

For decades, biology has relied on extracting cells, manipulating them externally, and reinfusing them back into patients. In vivo engineering flips that paradigm entirely by treating the body itself as the manufacturing site.

If researchers can solve delivery precision, safety, and scalability, CAR-T therapy could evolve from a rare, highly specialized procedure into a broadly deployable platform technology.

The implications would extend far beyond oncology.

The long-term vision is striking: injectable immune programming capable of rapidly rewriting cellular behavior inside the human body.

That vision is no longer science fiction.